[ad_1]
In eight days, this is the second positive result announced by a pharmaceutical company for its coronavirus vaccine. Last Monday, the American Pfizer and the German company BioNTech also announced that their vaccine had a 90% prevention rate.
“This positive interim analysis of the third phase of our trial gives the first clinical validation that our vaccine can prevent covid-19”, says Stéphane Bancel, CEO of Moderna, adding that this is a “remarkable” moment.
The two antidotes have one thing in common: they were designed with a base in RNA – ribonucleic acid, which results from the transcription of a sequence of genetic material – using inactive parts of the virus to stimulate the bodies’ immunity. This formula has never been used to make a vaccine that has received a “green light” from regulators.
But Moderna’s vaccine remains stable if refrigerated between 2 ° and 8 ° for 30 days, while the Pfizer-BioNTech vaccine only maintains all its components for 5 days at these temperatures, to activate your immune system against the virus must be between -70º and -80º, which can be an obstacle for its transport and storage.
“Cold transport will be one of the most challenging aspects for the application of this vaccine [da Pfizer]Amesh Adalja, an academic at the Johns Hopkins Center, told Reuters last week: “It will be challenging in all settings, because hospitals, even in large cities, do not have storage facilities for a vaccine at this ultra-low temperature.” , he said.
Of the 30,000 participants in the third testing phase, 95 were identified with covid-19, according to the company. Among those infected, only five people had to receive two doses of the vaccine, known as 1273 mRNA.
Now Moderna says it plans to submit its vaccine for approval by the Food and Drug Administration, the government’s regulatory agency, in the coming weeks. This means that at the end of this year there may be two vaccines approved by the North American entity.
[ad_2]
